Theratechnologies Inc. (THTX) |
|
2.4 -0.07 (-2.83%)
|
05-18 02:04 |
|
Open: |
2.46 |
Pre. Close: |
2.47 |
|
High:
|
2.49 |
Low:
|
2.4 |
|
Volume:
|
12,325 |
Market Cap:
|
228(M) |
|
|
|
|
Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA and EGRIFTA SV, for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo, an injection refers to ibalizumab for the treatment of multidrug resistant HIV-1 infected patients. Its pipeline products include F8 Formulation for the treatment of lipodystrophy in people living with HIV; TH1902, which is in Phase 1/Part A clinical trials for the treatment of triple negative breast cancer; and TH1904 for the treatment of ovarian cancer. The company was incorporated in 1993 and is headquartered in Montreal, Canada. |
Stock Price Prediction |
Update at 5:00pm EST |
|
If tomorrow:
|
Open lower
|
Open higher
|
|
High:
|
2.5 - 2.51 |
2.51 - 2.52 |
|
Low:
|
2.36 - 2.38 |
2.38 - 2.4 |
|
Close:
|
2.37 - 2.4 |
2.4 - 2.42 |
|
Technical analysis |
as of: 2022-05-17 4:50:40 PM |
|
Overall:
|
 |
| Stoxline posted a SELL today, same as yesterday. Downward movement continues. |
| Target: |
Six months: 3.15 One year: 3.68 |
| Support: |
Support1: 2.29 Support2: 2.04 |
| Resistance: |
Resistance1: 2.7 Resistance2: 3.15 |
| Pivot: |
2.47  |
| Moving Average: |
MA(5): 2.52 MA(20): 2.5
MA(100): 2.73 MA(250): 3.21 |
| MACD: |
MACD(12,26): -0.1 Signal(9): -0.1  |
| Stochastic oscillator: |
%K(14,3): 74.1 %D(3): 82 |
| RSI: |
RSI(14): 44.8 |
| 52-week: |
High: 4.46 Low: 2.04 |
| Average Vol(K): |
3-Month: 73 (K) 10-Days: 77 (K) |
|
Price, moving averages and Bollinger Bands |
|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ THTX ] has closed above bottom band by 31.4%. Bollinger Bands are 4.2% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices. |
|
|
Headline News |
Tue, 10 May 2022
Appointments in Conjunction With Theratechnologies Annual Meeting - Yahoo Finance
Wed, 27 Apr 2022
THERATECHNOLOGIES TO FOCUS ITS COMMERCIALIZATION ACTIVITIES ON THE NORTH AMERICAN TERRITORY - Yahoo Finance
Mon, 25 Apr 2022
Theratechnologies to Present at Bloom Burton & Co. Healthcare Investor Conference 2022 - Financial Post
Thu, 21 Apr 2022
Theratechnologies (NASDAQ:THTX) Cut to Sell at Zacks Investment Research - Defense World
Thu, 14 Apr 2022
Theratechnologies (NASDAQ:THTX) Posts Earnings Results, Misses Expectations By $0.02 EPS - Defense World
Wed, 13 Apr 2022
Theratechnologies Inc.'s (THTX) CEO Paul Levesque on Q1 2022 Results - Earnings Call Transcript - Seeking Alpha
|
Financial Analysis |
| Price to Book Value: |
Outperform |
| P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
| Price to Earnings: |
Underperform |
| PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
| Discounted cash flow: |
Outperform |
| DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
| Return on Assets: |
Neutral |
| ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
| Return on Equity: |
Underperform |
| ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
| Debt to Equity: |
Outperform |
| evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
|
|
|
|
|
|
| Free Technical Analysis Charts
|
|
|
Stock Basics & Statistics |
| Exchange: NASDAQ |
| Sector: Healthcare |
| Industry: Drug Manufacturers—Specialty & Generic |
| Shares Out. |
95 (M) |
| Shares Float |
86 (M) |
|
% Held by Insiders
|
1.2 (%) |
|
% Held by Institutions
|
25.2 (%) |
|
Shares Short
|
309 (K) |
|
Shares Short P.Month
|
281 (K) |
Stock Financials |
|
EPS
|
-0.32 |
|
EPS Est Next Qtl
|
0 |
|
EPS Est This Year
|
0 |
|
EPS Est Next Year
|
0 |
|
Book Value (p.s.)
|
0.28 |
|
Profit Margin (%)
|
-39 |
|
Operating Margin (%)
|
-30.4 |
|
Return on Assets (ttm)
|
-11.7 |
|
Return on Equity (ttm)
|
-154.7 |
|
Qtrly Rev. Growth
|
27.1 |
|
Gross Profit (p.s.)
|
0.46 |
|
Sales Per Share
|
0.73 |
|
EBITDA (p.s.)
|
-0.14 |
|
Qtrly Earnings Growth
|
0 |
|
Operating Cash Flow
|
-15 (M) |
|
Levered Free Cash Flow
|
-6 (M) |
Stock Valuations |
|
PE Ratio
|
-7.7 |
|
PEG Ratio
|
0 |
|
Price to Book value
|
8.57 |
|
Price to Sales
|
3.25 |
|
Price to Cash Flow
|
-15.24 |
Stock Dividends |
|
Dividend
|
0 |
|
Forward Dividend
|
0 |
|
Dividend Yield
|
0% |
|
Dividend Pay Date
|
Invalid DateTime. |
|
Ex-Dividend Date
|
Invalid DateTime. |
|
7 Binary Options
|
|
Your Ad Here
|
|
